Who owns Lyell Immunopharma, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Institutional ownership of LYEL from SEC Form 13F filings across 63 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 63 institutions disclosed 4.0M shares of Lyell Immunopharma, Inc. worth $54.8M — about 17.2% of shares outstanding; the largest disclosed holder is VANGUARD CAPITAL MANAGEMENT LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
63
13F holders
$54.8M
value, 2026 filers
17.2%
of shares outstanding (4.0M sh)
19
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of LYEL's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 786,774 | $11.1M | 0.0% | 3.4% | -45.2% |
| 2 | BlackRock, Inc. | 724,342 | $10.2M | 0.0% | 3.1% | +277.6% |
| 3 | MILLENNIUM MANAGEMENT LLC | 367,473 | $5.2M | 0.0% | 1.6% | -19.9% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 310,636 | $4.4M | 0.0% | 1.3% | +86.0% |
| 5 | Alphabet Inc. | 293,256 | $4.1M | 0.0% | 1.3% | 0.0% |
| 6 | NORTHERN TRUST CORP | 118,500 | $1.7M | 0.0% | 0.5% | +291.3% |
| 7 | Qube Research & Technologies Ltd | 110,531 | $1.6M | 0.0% | 0.5% | +100.6% |
| 8 | Sixth Street Partners Management Company, L.P.NEW | 107,570 | $1.5M | 0.3% | 0.5% | new |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 107,570 | $1.5M | 0.0% | 0.5% | +25.1% |
| 10 | MARSHALL WACE, LLP | 106,300 | $1.5M | 0.0% | 0.5% | -28.4% |
| 11 | VANGUARD FIDUCIARY TRUST CO | 93,095 | $1.3M | 0.0% | 0.4% | +7.1% |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 91,891 | $1.3M | 0.0% | 0.4% | +299.3% |
| 13 | MIC Capital Management UK LLP | 87,028 | $1.2M | 0.3% | 0.4% | 0.0% |
| 14 | GOLDMAN SACHS GROUP INC | 86,779 | $1.2M | 0.0% | 0.4% | -24.2% |
| 15 | ACADIAN ASSET MANAGEMENT LLCNEW | 59,748 | $836 | 0.0% | 0.3% | new |
| 16 | TWO SIGMA INVESTMENTS, LP | 52,927 | $743,624 | 0.0% | 0.2% | +356.9% |
| 17 | JANE STREET GROUP, LLC | 46,011 | $646,455 | 0.0% | 0.2% | -28.0% |
| 18 | Squarepoint Ops LLC | 42,322 | $594,624 | 0.0% | 0.2% | +119.4% |
| 19 | MORGAN STANLEY | 37,050 | $520,553 | 0.0% | 0.2% | -34.0% |
| 20 | HRT FINANCIAL LPNEW | 36,575 | $513 | 0.0% | 0.2% | new |
| 21 | PRICE T ROWE ASSOCIATES INC /MD/ | 30,657 | $431 | 0.0% | 0.1% | +133.5% |
| 22 | Point72 Asset Management, L.P. | 26,080 | $366,424 | 0.0% | 0.1% | +22.5% |
| 23 | UBS Group AG | 25,982 | $365,048 | 0.0% | 0.1% | -18.3% |
| 24 | Bank of New York Mellon CorpNEW | 24,673 | $346,656 | 0.0% | 0.1% | new |
| 25 | AMERICAN CENTURY COMPANIES INC | 24,540 | $344,787 | 0.0% | 0.1% | +53.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.